AI
Saturday, December 14, 2019 8:20:35 AM
Re: Vascepa & AMRN
miljenko >> as I see there should not be increase.[sales] My view is wrong, I can live with it, but I will not change bit of it. ... should be OTC drug
There is no question that a sound public policy argument can be made that EPA should be OTC. BUT it is not. FDA approved it, and expanded the label. Vascepa is supported by multiple patents that have neither been invalidated* nor expired.
Given this fact situation, sales WILL increase, likely to billions as most people on statins take Vascepa too.
Thus, there is a valid investment case to be made. IF the patents hold, it is all about valuation, valuation, and valuation.
It is not a cheap stock.
Jim
* There is a pending case to invalidate for obviousness, a loser IMO. Trial 1/13/2020
miljenko >> as I see there should not be increase.[sales] My view is wrong, I can live with it, but I will not change bit of it. ... should be OTC drug
There is no question that a sound public policy argument can be made that EPA should be OTC. BUT it is not. FDA approved it, and expanded the label. Vascepa is supported by multiple patents that have neither been invalidated* nor expired.
Given this fact situation, sales WILL increase, likely to billions as most people on statins take Vascepa too.
Thus, there is a valid investment case to be made. IF the patents hold, it is all about valuation, valuation, and valuation.
It is not a cheap stock. Jim
* There is a pending case to invalidate for obviousness, a loser IMO. Trial 1/13/2020
It is astonishing what foolish things one can temporarily believe if one thinks too long alone ... where it is often impossible to bring one's ideas to a conclusive test either formal or experimental. J.M. Keynes
Unleash the power of Level 2
Spot liquidity moves with access to US order books.
